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Hydroxymethylnitrofurazone (NFOH) is a new compound with potential leishmanicidal and trypanocidal 
activity. Despite its effectiveness, the formulators have to overcome its poor aqueous solubility. Recently, 
polymeric nano-scale drug delivery systems have proposed for the treatment of neglected diseases. 
As several studies have confirmed the advantages of such formulations, and this approach provides 
new analytical challenges, including the need to detect trace amounts of the drug. A suitable method 
was developed and validated for NFOH determination bound to poly (n-butylcyanoacrylate) (PBCA) 
nanoparticles. The chromatographic separation was achieved using a C18 column maintained at 25 ºC 
and an isocratic mobile phase consisting of water and acetonitrile: 80:20 (v/v) at a flow rate of 1.2 mL 
min-1 and UV-detection at 265 nm. Investigated validation parameters included selectivity, linearity, 
accuracy, precision and robustness (changes in column temperature, mobile phase composition and 
flow). The method was specific, the peak of NFOH had no interference with any nanoparticle excipients 
and no co-elution with main degradation product (nitrofurazone). Linearity was over the range of 
0.94‑13.11 μg mL-1 (r2=0.999). The method was accurate and precise, recovery of 100.7%, RSD of 
0.4%; intra‑day and inter‑day RSD range 9.98–9.99 μg mL-1 and 0.3% to 0.5%, respectively. Robustness 
confirmed that method could resist the applied changes. Application of the optimized method revealed an 
encapsulation efficiency of 64.4% (n=3). Therefore, the method was successfully developed and validated 
for the determination of the encapsulation efficiency of NFOH‑PBCA nanoparticles.
Uniterms: Hydroxymethylnitrofurazone/determinação. Nanoparticle. High‑performance liquid 
chromatography/reverse phase/quantitative analysis. Poly(n‑butylcyanoacrylate)/nanoparticles/
encapsulation.
Hidroximetilnitrofural (NFOH) é um novo composto que possui atividade leishmanicida e tripanomicida 
potencial. Um método apropriado foi desenvolvido e validado para a determinação de NFOH em 
nanopartículas de poli(n‑butil cianoacrilato) (PBCA). A separação cromatográfica foi obtida usando uma 
coluna C18 (5 µm de tamanho de partícula, 4,6 mm de diâmetro e 150 mm de comprimento), mantida 
a 25 °C, fase móvel composta de água e acetonitrila 80:20 (v/v), fluxo de 1,2 mL min- 1 e detecção 
por UV a 265 nm. Investigaram-se os seguintes parâmetros de validação: seletividade, linearidade, 
exatidão, precisão e robustez (mudanças na temperatura de coluna, proporção da fase móvel e fluxo). O 
método mostrou‑se específico, o pico de NFOH não apresentou interferência dos picos provenientes dos 
excipientes das nanopartículas e separado do principal produto de degradação (nitrofural). A linearidade 
foi obtida na faixa de 0,94-13,11 μg mL- 1 (r2=0,999). O método mostrou exatidão (recuperação de 100,7%, 
DPR de 0,4 %) e precisão (intra‑dia e inter‑dia, 9,98‑9,99 μg mL- 1 e DPR 0,3% a 0,5%, respectivamente). 
A robustez provou que o método pode resistir às mudanças propostas. Aplicação do método otimizado 
revelou eficiência de encapsulação de 64,4% (n=3). Portanto, o método foi desenvolvido e validado 
com sucesso para a determinação da eficiência de encapsulação de nanopartículas de NFOH‑PBCA.
Unitermos: Hidroximetilnitrofural/determinação. Nanopartículas. Cromatografia líquida de alta 
eficiência/fase reversa/análise quantitativa. Poli(n‑butilcianoacrilato)/nanopartículas/encapsulação.
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INTRODUCTION
The hydroxymethylnitrofurazone (NFOH) (Figure 
1) is a new compound with potential use to treat two 
neglected tropical diseases (NTDs): Chagas’ disease 
(Chung et al., 2003) and leishmaniasis. The treatment 
of both diseases requires parenteral administration for a 
prolonged period, causing severe adverse effects, such as 
cardiac, renal, pancreatic and liver impairment (World 
Health Organization, 2010; Schlossberg, 2008).
Chung and colleagues first obtained the NFOH 
using a molecular modification from its parent compound 
nitrofurazone (NF). The NFOH showed high activity 
in cell cultures infected with Trypanosoma cruzi and 
significant less toxicity than NF (Chung et al., 2003). 
Our group, using L. amazonensis, confirmed NFOH in 
vitro activity against Leishmania sp. Both parasites have 
similar metabolism and they belong to the same family: 
Trypanosomatidae (order Kinetoplastida) (Teixeira et 
al., 2012). Despite its effectiveness, the formulators have 
to overcome its poor aqueous solubility (Grillo et al., 
2008) aiming for the development of a new generation 
of antileismaniasis medicines. In this sense, nano-scale 
drug delivery systems can enable such medicines. 
This approach might have remarkable advantages over 
conventional formulations such as improving component 
solubility, enhancement of bioavailability, reducing dose, 
achieving constant therapeutic levels over an extend 
period of time, enhancement of stability and protection 
from physical and chemical degradation, among others 
(Bamrungsap et al., 2012; Faraji, Wipf, 2009; Parveen, 
Misra, Sahoo, 2012; Singh, Lillard Jr, 2009).
As several studies have confirmed, such formulations 
provide new analytical challenges, including the 
need to detect small amounts of drug. A significant 
number of techniques, especially high‑performance 
liquid chromatography (HPLC) are described for 
the quantification of drug encapsulation in PBCA 
nanoparticles (Shabir et al., 2007).
To the best of our knowledge, no previous reports exist 
in the literature outlining the concurrently development 
and validation of an HPLC method for the quantification of 
NFOH encapsulated with polymeric nanoparticles. Grillo 
et al. (2008) described a HPLC method for quantification 
of free NFOH and in an inclusion complex of NFOH 
and β‑cyclodextrin. When this method was applied to 
NFOH‑PBCA nanoparticles, one low response peak 
near the void volume time was found for all samples. 
These preliminary results showed the inadequacy of 
this method for the quantification of NFOH in PBCA. 
In the present work, we describe the development, 
validation and application of an analytical reversed-
phase HPLC‑UV method for the specific quantification 
of hydroxymethylnitrofurazone encapsulated in poly 
(n-butylcyanoacrylate) nanoparticles.
MATERIAL AND METHODS
Chemical and reagents
PBCA nanoparticles loaded with NFOH were 
obtained by emulsion polymerization as previously 
described (Tavares et al., 2011; Sham et al., 2004). Prof. 
Elizabeth Igne Ferreira, from FCF-USP (São Paulo, Brazil) 
provided hydroxymethylnitrofurazone from LAPEN 
(Laboratory of Design and Synthesis of Chemotherapeutic 
Agents Potentially Active on Neglected Diseases). The 
cyanoacrylate monomer was purchased from B. Braun 
Laboratories (Tuttlingen, Baden‑Württemberg, Germany) 
and dextran 70 from Sigma-Aldrich Corporation (St Louis, 
MO, USA). HPLC‑grade acetonitrile was acquired from 
EMD Chemicals Inc. (USA) and purified water from 
Milli-Q system (Millipore). All other chemicals and 
solvents were at least analytical grade.
Apparatus and chromatographic conditions
The chromatographic system was a Waters Alliance 
2695, equipped with a quaternary pump, a diode array 
detector and an automatic injector. For data collection and 
calculation, Empower 3 software was used. The analysis 
was performed under isocratic elution, using a Hypersyl 
Column, C18, 5 µm particle size, 4.6 X150 mm (Thermo, 
Waltham, MA, EUA), the improved mobile phase was 
composed of water and acetonitrile at a ratio 80:20 (v/v) 
maintained at 25 ºC. Measurements were performed 
at 265nm at a flow rate 1.2 mL min−1 with an injection 
volume of 20 µL. The NFOH peak was confirmed by its 
characteristic retention time of 4.9 minutes and spectrum.
Sample, standard solution and system suitability 
preparation
The sample solution for quantification of the 
FIGURE 1 - Chemical structure of NFOH.
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encapsulated compound was prepared transferring 
an aliquot of nanoparticles to an Eppendorf tube and 
centrifuged at 16.800 RFC (x g) 60 minutes, 25 ºC. 
The supernatant was filtered with 0.45 μm pore size 
PVDF-membrane (Millipore, Barcelona) and used for 
measurements. Unloaded nanoparticles solution was 
prepared transferring an aliquot of 1.0 mL of the PBCA 
nanoparticles suspension without NFOH to a 100 mL 
volumetric flask added with mobile phase. 
NFOH and NF standard stock solution (200 µg mL-1, 
50 μg mL-1) were prepared weighting NFOH and NF 
accurately and dissolving them, separately, in acetonitrile. 
NFOH standard solution (10 µg mL-1) was prepared 
from the NFOH stock solution, using mobile phase as 
diluent. System suitability solution (NFOH 10 µg mL-1, 
NF 1 µg mL-1) was prepared diluting the NFOH and NF 
stock solutions together with mobile phase. 
Before injecting the solutions, the following 
parameters were evaluated: resolution between NFOH 
and NF at least 2.0, the NFOH asymmetry peak less than 
1.5, theoretical plates more or equal than 2000 and NFOH 
retention time of 4.9 ±0.5 minutes.
Method development
Grillo et al.(2008) method was modified and the 
adjustments provided proper separation of NFOH from 
NF (main hydrolysis degradation product) and from 
the nanoparticle excipients. Additionally, the improved 
response made it possible to assess diluted solutions, since 
high encapsulation efficiency was expected (low amounts 
of NFOH in the supernatant).
Validation study
The validation process was performed according 
to the guideline outlined in The International Conference 
on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. 
Quality Guidelines. Analytical Validation Q2. Q2 (R1) ‑ 
validation of analytical procedures: text and methodology 
(ICH, 2005).
Selectivity
The selectivity of the method was evaluated in 
four different solutions: unloaded nanoparticle solution, 
nanostructured NFOH sample, mobile phase and standard 
NFOH. Spectral homogeneity was evaluated for all 
NFOH peaks in order to verify the absence of co‑elution 
of NFOH, NF and nanoparticle excipients.
Linearity
Linearity was evaluated using six NFOH standard 
solutions of 1.0, 4.0, 8.0, 10.0, 12.0 and 14.0 μg mL‑1 
added to unloaded nanoparticles. Each solution was 
prepared in three replicates. The experimental results 
were graphically plotted, obtaining a calibration curve 
and calculating y‑intercept, slope, VIF (variance inflation 
factor), correlation coefficients (r) and determination 
(r2), lack of fit test, PRESS (prediction sum of squares), 
standard deviation and Durbin –Watson statistic using 
Minitab® 16 and GraphPad Prim® 6.
Precision
The precision was assessed by test ing the 
repeatability of six sample solutions once on the same 
day (intra-day), and on a different day (inter-day). 
The two-sample t-test was applied to compare the 
means.
Accuracy
The recovery studies were conducted at three 
different levels of standard NFOH added with unloaded 
nanoparticles. The samples were prepared accordingly 
to the “sample preparation,” and the theoretical drug 
concentrations of 1.0, 10.0, and 14.0 μg mL-1 were 
prepared in three replicates each. The method accuracy 
was expressed as the average recovery and relative 
standard deviation (RSD).
Robustness
The robustness was evaluated using six replicates 
prepared according to the sample preparation described 
previously. The following variations were selected: column 
temperature (20 to 30 °C), mobile phase (75:25 and 85:15, 
water and acetonitrile), flow (1.1 and 1.3 mL min-1). The 
statistical evaluation was performed using ANOVA, after 
assuming the normality and equal variance of the data.
PBCA nanoparticles encapsulation efficiency 
(EE%) 
In literature, the EE of nanoparticles or microspheres 
is generally determined in an indirect way (Cournarie 
et al., 2004). The amount of drug encapsulated in 
nanoparticles was determined by the difference between 
the total amounts of drug and the entrapped drug after 
ultracentrifugation (Equation 1).
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EE% =
–
total amount
of drug
drug recovered
from supernatant
total amount of drug
× 100
( ) ( )
 (1)
RESULTS AND DISCUSSION
Method development and optimization
Initially the samples were analyzed using a mobile 
phase consisting of water: acetonitrile (20:80, v/v) as 
proposed by Grillo et al. (2008). Under these conditions, 
the resolution and peak symmetry were not acceptable. 
Therefore, an alternative mobile phase was investigated. 
After testing several proportions, the final composition 
was water: acetonitrile (80:20, v/v), under which a sharp 
peaks with suitable resolution of NFOH and NF (R≥2.0) 
were obtained (Figure 3D).
Although the peaks were well separated and 
symmetric, the NFOH peak height could not reach 0.04 
AU, even when 50 µL were injected, the response was not 
improved and the NFOH and NF peaks were co‑eluted. 
Further, the NFOH peak spectrum (Figure 2) revealed 
the wavelength could be altered from λ=210 nm (as 
proposed by Grillo et al., 2008) to maximum absorbance 
λ (λ = 265 nm). When applying the wavelength of 265 nm, 
the nanostructured NFOH sample reached 0.08AU. Thus, 
this wavelength was chosen as the best chromatographic 
response for this work.
Method validation
Selectivity
As recommended by ICH Q2(R1), a chromatographic 
method is considered selective when each peak within the 
chromatogram corresponds to only one substance (peak 
purity evaluation). In present work DAD analysis revealed 
peak purity for all NFOH samples. 
Moreover, a mixture of NFOH and NF standards 
and nanostructured NFOH samples chromatograms did 
not show any interferences (Figure 3). Likewise, unloaded 
nanoparticles and the mobile phase revealed no peak 
around NFOH retention time (4.9 min) (Figure 3). 
Therefore, the optimized method revealed itself 
selective for the quantification of NFOH.
Linearity
Although the method which has a correlation 
coefficient (r) greater than 0,99 can be accepted as linear, 
other statistics should be used to determine the quality 
of fit of the calibration curve, for example, the Durbin-
Watson statistic and the lack of fit test (Loco et al., 2002). 
The statistics presented in Table I exposes the linear 
characteristic of the method. With regard to the coefficients 
of determination and correlation, these were 0.999 and 
0.9999, respectively. These values, close to 1, and the results 
obtained for the test of lack of fit (p‑value> 0.1; α = 0.05) 
and the Durbin-Watson statistic (2.03826), indicate the 
suitability of proposed linear model. Additionally, the value 
of 1.00 for the variance inflation factor (VIF) showed the 
absence of multicollinearity. With regard to the PRESS 
statistic, the value was equal to 0.767 and therefore 
considered adequate (value <1.0) (Montgomery, Peck, 
Vining, 2001).
Precision
The measurement precision was evaluated by 
performing six replicate samples of nanostructured NFOH 
at 100% of the method concentration (10 µg mL-1) in the 
same day (intra-day) and after 2 days (inter-day). For intra-
day analysis the precision was 0.34%; as for inter-day, CV 
was 0.49%, (Table II) which complies with the acceptance 
criteria proposed by the ICH Q2(R1) (CV < 2.0%). The 
p-value of the two-sample t-test was 0.692 (α=0.05), which 
means that the null hypothesis was accepted. Thus, these 
values have no significant difference between their means. 
Therefore, these results indicate that the proposed method 
presented adequate precision.
Accuracy
The average recoveries percentage of the spiked 
FIGURE 2 - Hydroxymethylnitrofurazone spectrum. 
Chromatographic conditions: mobile phase water and 
acetonitrile 80:20 (v/v), flow of 1.2 mL min-1, injection volume 
of 20 μL, column temperature of 25 ºC.
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NFOH was 100.7%, while %RSD value was 0.6% 
(Table 4) indicating accuracy of the reported method, once 
it met the acceptance ICH Q2(R1) criteria (RSD<2%).
Robustness
Minor deliberate changes in different experimental 
parameters did not significantly affect the recoveries 
(Table IV). This outcome was confirmed when the 
mean values were compared through ANOVA. The null 
hypothesis was accepted (p‑value equal to 0.053, α=0.05). 
Therefore, no significant difference between means was 
found, reiterating the method robustness.
Method application
Encapsulation efficiency (EE)
The application of the proposed method for 
the quantification of NFOH in PBCA nanoparticles 
revealed encapsulation efficiency of NFOH in PBCA 
nanoparticles of 64.4 RSD 0.4% (n=3). No alterations 
in the chromatograms or unusual peaks were observed 
during validation.
CONCLUSION
A RP‑HPLC method was successfully developed 
and validated for the quantification of NFOH bound 
to PBCA nanoparticles. The described method has no 
FIGURE 3 - Selectivity chromatograms. Mobile phase: water and acetonitrile 80:20 (v/v), flow: 1.2 mL min-1, λ: UV 265 nm, 
injection volume: 20 μL, column temperature: 25ºC. NFOH: hydroxymethylnitrofurazone, NF: nitrofurazone.
TABLE I - Statistical analysis evaluation of the linear regression, 
N=3
Statistical Regression Analysis
Slope 57254
Intercept - 3265
Coefficient of correlation (r) 0,9999
VIF (variance inflation factor) 1.000
Coefficient of determination (r2) 0.9990
Durbin – Watson 
Lack of fit 
PRESS (prediction sum of squares) 
Standard deviation
2,0355 
p‑value> 0.1 
0.0767 
0.0453
TABLE II - Precision results for different levels of nanostructured 
NFOH
Precision
NFOH 
concentration 
(μg mL-1)*
Two-Sample t-test
Intra-day 9.98 p- value 0.692
CV (%) 0.34
Inter-day 9.99
CV (%) 0.49
*Expressed as the mean of six replicates
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interference from excipients, allowing the quantification 
of NFOH in these formulations with highy accuracy. The 
method revealed to be simple, accurate and precise and 
could be easily applied in the determination of NFOH and 
its main degradation product when used with nanoparticles 
as drug carrier.
ACKNOWLEDGMENTS
The authors are grateful to CNPq (National Council 
for Scientific and Technological Development) for financial 
support and to United States Pharmacopeia (Tamboré, 
Brazil), for material, equipment and installations.
REFERENCES
BAMRUNGSAP, S.; ZHAO, Z.; CHEN, T.; WANG, L.; LI, C.; 
FU, T.; TAN, W. Nanotechnology in therapeutics: a focus 
on nanoparticles as a drug delivery system. Nanomedicine 
(London), v.7, n.8, p.1253-1271, 2012.
CHUNG, M.C.;  GÜIDO, R.V.;  MARTINELLI,  T.F.; 
GONÇALVES, M.F.; POLLI, M.C.; BOTELHO, K.C.; 
VARANDA, E.A.; COLLI, W.; MIRANDA, M.T.; 
FERREIRA, E.I. Synthesis and in Vitro evaluation of 
potential antichagasic hydroxymethylnitrofurazone 
(NFOH-121): a new nitrofurazone prodrug. Bioorg. Med. 
Chem., v.11, n.22, p.4779-4783, 2003.
COURNARIE, F.; CHERON, M.; BESNARD, M.; VAUTHIER, 
C. Evidence for restrictive parameters in formulation of 
insulin-loaded nanocapsules. Eur. J. Pharm. Biopharm., 
v.57, n.2, p.171-179, 2004.
FARAJI, A.H.; WIPF, P. Nanoparticles in cellular drug delivery. 
Bioorg. Med. Chem., v.17, n.8, p.2950-2962, 2009.
ICH. International conference on harmonisation of technical 
requirements for registration of pharmaceuticals for human 
use. Quality Guideline. View All Quality Guidelines. 
Analytical Validation Q2. Q2 (R1) ‑ validation of analytical 
procedures: text and methodology. S.l.: ICH, 2005. 
Available at: <http://www.ich.org/fileadmin/Public_Web_
Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/
Q2_R1__Guideline.pdf>. Accessed on: 23 Jan. 2012.
GRILLO, R.; DE MELO, N.F.; MORAES, C.M.; DE LIMA, 
R.; MENEZES, C.M.; FERREIRA, E.I.; ROSA, A.H.; 
FRACETO, L.F. Study of the interaction between 
hydroxymethylnitrofurazone and 2-hydroxypropyl-beta-
cyclodextrin. J. Pharm. Biomed. Anal., v.47, n.2, p.295-
302, 2008.
LOPES, R.; ELEUTÉRIO, C.V.; GONÇALVES, L.M.D.; 
CRUZ, M.E.M.; ALMEIDA, A.J. Lipid nanoparticles 
containing oryzalin for the treatment of leishmaniasis. Eur. 
J. Pharm. Sci., v.45, n.4, p.442-450, 2012.
LOCO, J.V.; ELSKENS, M.; CROUX, C.; BEERNAERT, 
H. Linearity of calibration curves: use and misuse of the 
correlation coefficient. Accred. Qual. Assur., v.7, p.281-
285, 2002.
MONTGOMERY, D.C.; PECK, E.A.; VINING, G.G. 
Introduction to linear regression analysis. 3.ed. New York: 
Wiley, 2001. 612 p.
PARVEEN, S.; MISRA, R.; SAHOO, S.K. Nanoparticles: 
a boon to drug delivery, therapeutics, diagnostics and 
imaging. Nanomedicine, v.8, n.2, p.147-166, 2012.
TABLE III - Accuracy results for different levels of NFOH in standard solutions
Amount added 
(μg mL-1)*
Amount recovered 
(μg mL-1)*
Recovery 
(%)*
Average Recovery 
(%)
NFOH 0.9363 0.9372 100.1
100.7 
RSD 0.6
9.3633 9.4476 100.9
13.1082 13.2655 101.2
*Expressed as the mean of three replicates
TABLE IV - Variations in the chromatographic conditions 
evaluation the robustness
Condition Mean (%) RSD (%)
Initial 100.3 0.3
Water acetonitrile 75:25 100.7 0.2
Water acetonitrile 85:15 100.7 0.2
Flow 1.1 mL min-1 100.8 0.2
Flow 1.3 mL min-1 100.7 0.3
Column 20 °C 100.7 0.2
Column 30 °C 100.5 0.2
Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone 567
SCHLOSSBERG, D. Clinical infectious disease. 1ed. New 
York: Cambridge University Press, 2008. 1392 p.
SHABIR, G.A.; LOUGH, J.W.; ARAIN, S.A.; BRADSHAW, 
T.K. Evaluation and application of best practice in analytical 
method validation. J. Liq. Chromatogr. Relat. Technol., v.30, 
n.3, p.311-333, 2007.
SHAM, J.O.; ZHANG, Y.; FINLAY, W.H.; ROA, W.H.; 
LOBENBERG, R. Formulation and characterization of 
spray-dried powders containing nanoparticles for aerosol 
delivery to the lung. Int. J. Pharm., v.28, n.269, p.457-467, 
2004.
SINGH, R.; LILLARD JR, J.W. Nanoparticle-based targeted 
drug delivery. Exp. Mol. Pathol., v.86, n.3, p.215-223, 2009.
TAVARES, G.M.; ISHIKAWA, G.M.; MONTEIRO, T.F.; 
ZANOLINI, C.; KEDOR‑HACKMANN, E.R.M.; 
BOU‑CHACRA, N.A.; CONSIGLIERI, V.O. Derivative 
spectrophotometric method for determination of acyclovir 
in polymeric nanoparticles. Quím. Nova, v.35, n.1, p.203-
206, 2011.
T E I X E I R A, S .M.;  PA I VA, R.M.C.;  K A N G U S S U‑
MARCOLINO, M.M.; ROCHA, W. Trypanosomatid 
comparative genomics: contributions to the study of parasite 
biology and different parasitic diseases. Genet. Mol. Biol., 
v.35, n.1, p.1-17, 2012.
WORLD HEALTH ORGANIZATION. WHO. Control of the 
Leishmaniasis: report of a meeting of the WHO expert 
committee on the control of leishmaniases. Geneva: WHO, 
2010. 186 p. (WHO technical report series, 949).
Received for publication on 04th June 2014
Accepted for publication on 29th July 2015

